Previous Close | 1.8500 |
Open | 1.8500 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 1.8500 - 1.8500 |
52 Week Range | 0.9000 - 2.9700 |
Volume | |
Avg. Volume | 98 |
Market Cap | 89.061M |
Beta (5Y Monthly) | 0.35 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.2400 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 11.40 |
Subscribe to Yahoo Finance Plus to view Fair Value for BRSYF
Data Published in Leading Peer-Reviewed Publication, Journal of Clinical MedicineJERUSALEM and BURLINGTON, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced positive results in a recently published post-marketing study of its Deep Transcranial Magnetic Stimulation (Deep TMS™) for the treatment of late-life depression. The data wer
Brainsway (BWAY) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Brainsway Ltd. Sponsored ADR (BWAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.